We never settle and now we are creating a new paradigm with a first-in-class therapy in Autoimmune Diabetes (Type 1 Diabetes).
Our newest core asset, resulting from the acquisition of Provention Bio in General Medicines Autoimmune Type 1 Diabetes space, aims at delaying the onset of stage 3 type 1 diabetes. This means that for the first time, people at risk of developing this lifelong disease have fresh hope. What delayed onset means is more time for children to be children with less healthcare and more care-free childhood. The delay also gives families and healthcare professionals more time to prepare care plans for a later diagnosis.
As a MSL - Autoimmune T1D Specialist, you will be the trusted scientific partner for external experts and decision-makers, while also contributing to the development and implementation of screening and monitoring s...